Key result
Altered estrogen metabolism and sex hormone signaling may drive the strong female predominance in PAH.
Why the study?
Female predominance in pulmonary arterial hypertension has been known for decades, but the mechanisms underlying this gender difference remain largely unknown.
May inform sex-specific PAH risk models; leaves open whether targeting estrogen pathways alters outcomes.
Female predominance in pulmonary arterial hypertension (PAH) has been known for several decades and recent interest in the effects of sex hormones on the development of disease has substantially increased our understanding of this epidemiologic observation. Basic science data suggest a beneficial effect of estrogens in the pulmonary vasculature both acutely and chronically, which seems to contradict the known predilection in women. Recent human and rodent data have suggested that altered levels of estrogen, differential signaling and altered metabolism of estrogens in PAH may underlie the gender difference in this disease. Studies of the effects of sex hormones on the right ventricle in animal and human disease will further aid in understanding gender differences in PAH. This article focuses on the effects of sex hormones on the pulmonary vasculature and right ventricle on both a basic science and translational level.
No takes yet. Share an insight, caveat, or question.
Pugh et al. (2010) conducted a review in Pulmonary arterial hypertension. Sex hormones (estrogens, testosterone, DHEA) was evaluated. Altered estrogen metabolism and differential sex hormone signaling may underlie the strong female predominance observed in pulmonary arterial hypertension.